Restart Life Closes Over-Subscribed Second Tranche Financing

Core Viewpoint - Restart Life Sciences Corp. has successfully closed the over-subscribed second tranche of its non-brokered private placement, raising a total of CDN$1,130,000, exceeding its initial target of CDN$1,000,000 due to high investor interest [1]. Group 1: Private Placement Details - The second tranche of the private placement involved the issuance of 6,300,000 units at a price of CDN$0.10 per unit, with each unit comprising one common share and one transferable common share purchase warrant [2]. - Each warrant allows the holder to purchase an additional common share for one year at a price of CDN$0.10 per share [2]. - The company also issued 132,000 non-transferable finder warrants to eligible finders, with similar terms as the purchase warrants [3]. Group 2: Use of Proceeds - The proceeds from the private placement will be allocated towards health food trials, potential acquisitions, and general working capital [4]. - All securities issued under the placement are subject to a hold period of four months and one day, expiring on April 18, 2026 [4]. Group 3: Company Overview - Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the Canadian Securities Exchange [5].